Skip to main content

Table 5 Postoperative pathologic staging in patients who underwent surgery

From: Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Pathologic stage

FEC arm [cases (%)]

PE arm [cases (%)]

P value

Total

132

130

 

pT stage

  

0.001

 0

11 (8.33)

15 (11.53)

 

 DCIS

7 (5.30)

7 (5.38)

 

 1

40 (30.30)

62 (47.69)

 

 2

57 (43.18)

41 (31.54)

 

 3

2 (1.52)

2 (1.54)

 

 4

15 (11.36)

3 (2.31)

 

pN stage

  

0.001

 0

46 (34.85)

51 (39.23)

 

 1

39 (29.55)

39 (30.00)

 

 2

25 (18.94)

18 (13.85)

 

 3

22 (16.67)

22 (16.92)

 
  1. FEC tri-weekly 5-fluorouracil–epirubicin–cyclophosphamide regimen, PE weekly paclitaxel–epirubicin regimen, DCIS ductal carcinoma in situ
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us